Bortezomib induces heme oxygenase-1 expression in multiple myeloma

References

• Harousseau J-L, Dreyling M, ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19:Suppl 2 ii55 - 7; http://dx.doi.org/10.1093/annonc/mdn088; PMID: 18456769
   PubMedGoogle Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764 - 7; http://dx.doi.org/10.1182/blood-2011-08-373514; PMID: 22323483
   PubMed Web of Science ®Google Scholar
• Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, et al. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol 2012; 88:446 - 9; http://dx.doi.org/10.1111/j.1600-0609.2012.01765.x; PMID: 22300348
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101:4098 - 104; http://dx.doi.org/10.1182/blood-2002-08-2512; PMID: 12531810
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011; 71:1999 - 2009; http://dx.doi.org/10.1158/0008-5472.CAN-10-3018; PMID: 21212410
   PubMed Web of Science ®Google Scholar
• Schäfer M, Dütsch S, auf dem Keller U, Werner S. Nrf2: a central regulator of UV protection in the epidermis. Cell Cycle 2010; 9:2917 - 8; http://dx.doi.org/10.4161/cc.9.15.12701; PMID: 20699662
   PubMed Web of Science ®Google Scholar
• Alam J, Stewart D, Touchard C, Boinapally S, Choi AMK, Cook JL. Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999; 274:26071 - 8; http://dx.doi.org/10.1074/jbc.274.37.26071; PMID: 10473555
   PubMed Web of Science ®Google Scholar
• Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275:16023 - 9; http://dx.doi.org/10.1074/jbc.275.21.16023; PMID: 10821856
   PubMed Web of Science ®Google Scholar
• Villeneuve NF, Sun Z, Chen W, Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell Cycle 2009; 8:3255 - 6; http://dx.doi.org/10.4161/cc.8.20.9565; PMID: 19806015
   PubMed Web of Science ®Google Scholar
• Sun J, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002; 21:5216 - 24; http://dx.doi.org/10.1093/emboj/cdf516; PMID: 12356737
   PubMed Web of Science ®Google Scholar
• Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem 2005; 280:16891 - 900; http://dx.doi.org/10.1074/jbc.M500166200; PMID: 15734732
   PubMed Web of Science ®Google Scholar
• Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-κ B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 1994; 91:5987 - 91; http://dx.doi.org/10.1073/pnas.91.13.5987; PMID: 8016102
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Bowles KM, Raninga P, MacEwan DJNF. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res 2010; 70:2973 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-09-3407; PMID: 20332229
   PubMed Web of Science ®Google Scholar
• Kirino Y, Takeno M, Murakami S, Kobayashi M, Kobayashi H, Miura K, et al. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum 2007; 56:464 - 75; http://dx.doi.org/10.1002/art.22370; PMID: 17265482
   PubMed Web of Science ®Google Scholar
• Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6:15 - 24; http://dx.doi.org/10.1023/A:1025803600840; PMID: 14517400
   PubMedGoogle Scholar
• Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359 - 66; PMID: 21307400
   PubMed Web of Science ®Google Scholar
• Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, MacEwan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2011; 2:658 - 68; PMID: 21911919
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 2004; 64:3148 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-03-1200; PMID: 15126353
   PubMed Web of Science ®Google Scholar
• Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, et al. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Apoptosis 2009; 14:298 - 308; http://dx.doi.org/10.1007/s10495-008-0305-7; PMID: 19153832
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger KJ, et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008; 111:2200 - 10; http://dx.doi.org/10.1182/blood-2006-11-055723; PMID: 18024796
   PubMed Web of Science ®Google Scholar
• Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008; 111:3793 - 801; http://dx.doi.org/10.1182/blood-2007-07-104042; PMID: 18202225
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, et al. Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci 2010; 101:1409 - 16; http://dx.doi.org/10.1111/j.1349-7006.2010.01550.x; PMID: 20345481
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34:176 - 88; http://dx.doi.org/10.1016/j.tibs.2008.12.008; PMID: 19321346
   PubMed Web of Science ®Google Scholar
• Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373:151 - 4; http://dx.doi.org/10.1016/j.bbrc.2008.06.004; PMID: 18555005
   PubMed Web of Science ®Google Scholar
• Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, et al. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34(+)/CD38(+) and CD34(+)/CD38(-) AML progenitor cells. Curr Cancer Drug Targets 2012; 12:51 - 63; http://dx.doi.org/10.2174/156800912798888992; PMID: 22165967
   PubMed Web of Science ®Google Scholar
• Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CCN, et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010; 107:7479 - 84; http://dx.doi.org/10.1073/pnas.1002890107; PMID: 20368435
   PubMed Web of Science ®Google Scholar
• Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, et al. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol 2011; 224:90 - 100; http://dx.doi.org/10.1002/path.2855; PMID: 21381033
   PubMed Web of Science ®Google Scholar
• Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, et al. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 2011; In press http://dx.doi.org/10.1002/cncr.26621; PMID: 22139798
   PubMed Web of Science ®Google Scholar
• Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 2005; 128:636 - 44; http://dx.doi.org/10.1111/j.1365-2141.2005.05369.x; PMID: 15725085
   PubMed Web of Science ®Google Scholar
• Bancos S, Baglole CJ, Rahman I, Phipps RP. Induction of heme oxygenase-1 in normal and malignant B lymphocytes by 15-deoxy-Δ(12,14)-prostaglandin J(2) requires Nrf2. Cell Immunol 2010; 262:18 - 27; http://dx.doi.org/10.1016/j.cellimm.2009.12.003; PMID: 20064636
   PubMed Web of Science ®Google Scholar